Under the terms of the agreements, each company will license Cisbio's HTRF technology for use in their high-performance time-resolved fluorescence microplate readers that are used in HTRF-based assays.
Cisbio also announced today that it has signed collaborations with Cell Signaling Technology and Upstate to expand use of the HTRF technology.
According to Cisbio, Cell Signaling has agreed to supply a select group of native antibodies and substrates that Cisbio will label and market for use in conjunction with HTRF. Separately, Upstate has agreed to use the HTRF technology with its assay for PI-3 kinase.
Additional terms of all five deals were not disclosed.